Perspective Therapeutics (CATX) News Today $6.16 -0.62 (-9.14%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical SymposiumNovember 21 at 7:15 AM | globenewswire.comPerspective Therapeutics (CATX) Receives a Buy from RBC CapitalNovember 20 at 10:18 AM | markets.businessinsider.comFY2024 EPS Estimates for CATX Lifted by Cantor FitzgeraldNovember 18 at 2:31 AM | americanbankingnews.comCATX FY2024 EPS Estimate Boosted by Cantor FitzgeraldPerspective Therapeutics, Inc. (NYSE:CATX - Free Report) - Stock analysts at Cantor Fitzgerald upped their FY2024 earnings per share estimates for shares of Perspective Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now expects that the cNovember 18 at 2:30 AM | marketbeat.comPerspective Therapeutics, Inc. to Present Initial Results of [212Pb]VMT-α-NET Phase 1/2a Trial at NANETS SymposiumNovember 15, 2024 | quiverquant.comPerspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024November 15, 2024 | globenewswire.comOptimistic Outlook for Perspective Therapeutics Amid Promising Trial DevelopmentsNovember 14, 2024 | markets.businessinsider.comPerspective Therapeutics Reports Strong Cash Position and Clinical AdvancesNovember 14, 2024 | markets.businessinsider.comBuy Rating for Perspective Therapeutics Due to Clinical Progress and Strategic Manufacturing ExpansionNovember 13, 2024 | markets.businessinsider.comPerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 ResultsNovember 12, 2024 | globenewswire.comPerspective Therapeutics Q3 2024 Earnings PreviewNovember 12, 2024 | msn.comWealthPlan Investment Management LLC Invests $4.53 Million in Perspective Therapeutics, Inc. (NYSE:CATX)WealthPlan Investment Management LLC bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 339,292 shares of the company's stock, vaNovember 12, 2024 | marketbeat.comPerspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of "Buy" from AnalystsPerspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) has been assigned a consensus rating of "Buy" from the ten ratings firms that are covering the company, MarketBeat reports. Ten research analysts have rated the stock with a buy recommendation. The average 12 month price target among broNovember 5, 2024 | marketbeat.comHills Bank & Trust Co Invests $13.72 Million in Perspective Therapeutics, Inc. (NYSE:CATX)Hills Bank & Trust Co bought a new position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,027,830 shares of the company's stock,November 1, 2024 | marketbeat.comPerspective Therapeutics (AMEX:CATX) Stock, Short Interest ReportNovember 1, 2024 | benzinga.comPerspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial ResultsNovember 1, 2024 | markets.businessinsider.comPerspective Therapeutics to Participate in Upcoming Investor Conferences in NovemberOctober 29, 2024 | globenewswire.comPerspective Therapeutics initiated with a Buy at UBSOctober 25, 2024 | markets.businessinsider.comWedbush Sticks to Its Buy Rating for Perspective Therapeutics (CATX)October 25, 2024 | markets.businessinsider.comNicholson Wealth Management Group LLC Acquires New Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)Nicholson Wealth Management Group LLC purchased a new position in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,602,283 sOctober 25, 2024 | marketbeat.comUBS Initiates Coverage of Perspective Therapeutics (CATX) with Buy RecommendationOctober 24, 2024 | msn.comPerspective Therapeutics (NYSE:CATX) Shares Gap Up - Here's What HappenedPerspective Therapeutics (NYSE:CATX) Shares Gap Up - Here's WhyOctober 24, 2024 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Receives "Outperform" Rating from WedbushWedbush reissued an "outperform" rating and issued a $20.00 price target on shares of Perspective Therapeutics in a report on Thursday.October 24, 2024 | marketbeat.comUBS Group Begins Coverage on Perspective Therapeutics (NYSE:CATX)UBS Group began coverage on shares of Perspective Therapeutics in a research note on Thursday. They issued a "buy" rating and a $20.00 price objective for the company.October 24, 2024 | marketbeat.comPerspective Therapeutics presents updates at 37th Annual Congress of EANMOctober 23, 2024 | markets.businessinsider.comPerspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear MedicineOctober 23, 2024 | globenewswire.comPerspective Therapeutics (CATX) Gets a Buy from Truist FinancialOctober 18, 2024 | markets.businessinsider.comPerspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New JerseyOctober 16, 2024 | globenewswire.comPerspective Therapeutics (NYSE:CATX) Trading Up 4.9% - Should You Buy?Perspective Therapeutics (NYSE:CATX) Shares Up 4.9% - Here's What HappenedOctober 15, 2024 | marketbeat.comPerspective Therapeutics (NYSE:CATX) Sees Large Volume Increase - What's Next?Perspective Therapeutics (NYSE:CATX) Sees Unusually-High Trading Volume - Here's WhyOctober 14, 2024 | marketbeat.comPerspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer TherapiesOctober 12, 2024 | msn.comPerspective Therapeutics (AMEX:CATX) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comMaintained Buy Rating on CATX Amid Adjusted Success Probabilities and Clinical HurdlesOctober 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Perspective Therapeutics Amid Promising Early-Stage Drug Results for Melanoma TreatmentOctober 11, 2024 | markets.businessinsider.comPerspective Therapeutics Shares Fall After Melanoma Study Data AnalysisOctober 11, 2024 | marketwatch.comCancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study ReportOctober 11, 2024 | benzinga.comPerspective falls after data for radiopharmaceutical in skin cancerOctober 11, 2024 | msn.comOppenheimer Sticks to Their Buy Rating for Perspective Therapeutics (CATX)October 11, 2024 | markets.businessinsider.comPerspective Therapeutics (NYSE:CATX) Shares Gap Down - Should You Sell?Perspective Therapeutics (NYSE:CATX) Shares Gap Down - Here's WhyOctober 11, 2024 | marketbeat.comPerspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma ResearchOctober 11, 2024 | globenewswire.comPerspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of "Buy" by BrokeragesShares of Perspective Therapeutics, Inc. (NYSE:CATX - Get Free Report) have earned a consensus rating of "Buy" from the nine ratings firms that are covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendatOctober 11, 2024 | marketbeat.comPerspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma ResearchOctober 10, 2024 | globenewswire.comPerspective Therapeutics (NYSE:CATX) Shares Down 3.6% - What's Next?Perspective Therapeutics (NYSE:CATX) Stock Price Down 3.6% - Here's What HappenedOctober 9, 2024 | marketbeat.comPerspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma DayOctober 7, 2024 | globenewswire.comPoint72 Asset Management L.P. Sells 13,250,683 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)Point72 Asset Management L.P. cut its stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 98.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 202,572 shares of the company's stock after seOctober 4, 2024 | marketbeat.comPerspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-ConceptOctober 2, 2024 | seekingalpha.comPerspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2October 2, 2024 | gurufocus.comPerspective Therapeutics (NYSE:CATX) Upgraded by Wedbush to Strong-BuyWedbush upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Monday.October 2, 2024 | marketbeat.comBuy Rating on Perspective Therapeutics Backed by Promising VMT-alpha-NET Clinical ResultsOctober 2, 2024 | markets.businessinsider.comPerspective Therapeutics a new buy at Wedbush on radiopharmaceutical assetsOctober 2, 2024 | seekingalpha.com Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide CATX Media Mentions By Week CATX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CATX News Sentiment▼0.780.46▲Average Medical News Sentiment CATX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CATX Articles This Week▼83▲CATX Articles Average Week Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TNDM News RXST News NVCR News INMD News MDXG News AORT News ESTA News PLSE News BLFS News BVS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:CATX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.